Novo Nordisk A/S (NVO) DCF Valuation

Novo Nordisk A/S (NVO) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Novo Nordisk A/S (NVO) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Simplify Novo Nordisk A/S (NVO) valuation with this customizable DCF Calculator! Featuring real Novo Nordisk A/S (NVO) financials and adjustable forecast inputs, you can test scenarios and uncover Novo Nordisk A/S (NVO) fair value in minutes.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 17,063.5 17,752.2 19,689.5 24,745.3 32,479.5 38,316.2 45,201.8 53,324.8 62,907.6 74,212.4
Revenue Growth, % 0 4.04 10.91 25.68 31.26 17.97 17.97 17.97 17.97 17.97
EBITDA 8,081.5 8,288.8 9,144.7 11,472.5 16,029.8 18,101.6 21,354.6 25,192.1 29,719.2 35,059.9
EBITDA, % 47.36 46.69 46.44 46.36 49.35 47.24 47.24 47.24 47.24 47.24
Depreciation 654.3 737.8 742.7 923.2 1,316.3 1,497.9 1,767.1 2,084.6 2,459.2 2,901.2
Depreciation, % 3.83 4.16 3.77 3.73 4.05 3.91 3.91 3.91 3.91 3.91
EBIT 7,427.2 7,551.0 8,402.0 10,549.3 14,713.4 16,603.7 19,587.5 23,107.5 27,260.0 32,158.8
EBIT, % 43.53 42.54 42.67 42.63 45.3 43.33 43.33 43.33 43.33 43.33
Total Cash 2,164.0 1,783.9 2,445.1 3,296.6 4,227.4 4,711.9 5,558.7 6,557.6 7,736.0 9,126.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 4,076.6 4,500.6 6,544.4 8,041.5 10,524.5
Account Receivables, % 23.89 25.35 33.24 32.5 32.4
Inventories 2,466.9 2,592.1 2,743.8 3,410.4 4,448.5 5,400.5 6,371.0 7,515.9 8,866.5 10,459.9
Inventories, % 14.46 14.6 13.94 13.78 13.7 14.09 14.09 14.09 14.09 14.09
Accounts Payable 889.1 799.5 1,240.4 2,179.7 3,580.8 2,747.0 3,240.7 3,823.1 4,510.1 5,320.6
Accounts Payable, % 5.21 4.5 6.3 8.81 11.02 7.17 7.17 7.17 7.17 7.17
Capital Expenditure -1,570.5 -3,087.8 -1,032.7 -2,063.1 -5,439.2 -4,362.5 -5,146.4 -6,071.3 -7,162.3 -8,449.4
Capital Expenditure, % -9.2 -17.39 -5.25 -8.34 -16.75 -11.39 -11.39 -11.39 -11.39 -11.39
Tax Rate, % 20.05 20.05 20.05 20.05 20.05 20.05 20.05 20.05 20.05 20.05
EBITAT 5,958.4 5,988.8 6,791.7 8,481.5 11,762.9 13,306.7 15,698.0 18,519.0 21,846.9 25,773.0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -612.3 2,999.9 4,747.1 6,117.2 5,520.0 7,886.7 9,812.2 11,575.5 13,655.6 16,109.6
WACC, % 5.38 5.38 5.38 5.38 5.38 5.38 5.38 5.38 5.38 5.38
PV UFCF
SUM PV UFCF 49,686.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 16,432
Terminal Value 486,639
Present Terminal Value 374,529
Enterprise Value 424,216
Net Debt 1,764
Equity Value 422,452
Diluted Shares Outstanding, MM 4,495
Equity Value Per Share 93.99

What You Will Get

  • Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real NVO financials.
  • Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
  • Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
  • Automatic Calculations: Instantly observe the effects of your inputs on Novo Nordisk’s valuation.
  • Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
  • User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.

Key Features

  • Real-Life NVO Data: Pre-filled with Novo Nordisk’s historical financials and forward-looking projections.
  • Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
  • Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
  • Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
  • User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Novo Nordisk A/S (NVO) data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Novo Nordisk A/S (NVO)’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Novo Nordisk A/S (NVO)?

  • Accurate Data: Up-to-date Novo Nordisk financials provide trustworthy valuation outcomes.
  • Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Pre-configured calculations save you from starting from the ground up.
  • Professional-Grade Tool: Tailored for investors, analysts, and consultants in the healthcare sector.
  • User-Friendly: Intuitive design and guided instructions make it accessible for all users.

Who Should Use Novo Nordisk A/S (NVO)?

  • Healthcare Investors: Make informed investment choices with insights from a leading pharmaceutical company.
  • Market Analysts: Access comprehensive data to streamline your research on diabetes and obesity treatments.
  • Healthcare Consultants: Tailor presentations and reports with up-to-date information on Novo Nordisk's product pipeline.
  • Pharmaceutical Enthusiasts: Enhance your knowledge of the biopharmaceutical industry through real-life case studies.
  • Students and Educators: Utilize it as a resource for learning about biotechnology and healthcare economics.

What the Template Contains

  • Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Novo Nordisk A/S (NVO).
  • Real-World Data: Novo Nordisk’s historical and projected financials preloaded for thorough analysis.
  • Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
  • Key Ratios: Built-in analysis covering profitability, efficiency, and leverage metrics.
  • Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results regarding Novo Nordisk A/S (NVO).

No products were found matching.